top of page
2021 Poster Display

GHAPP 2021 Conference Virtual Poster Display

Baum_GHAPP21 1125 Insulin Resistance poster_KL05_FINAL_UPLOAD.jpg

LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects With NAFLD and T2D

Dellon et al. EoE Phase 3 Part A primary_GHAPP 2021_poster-Sep 3.jpg

Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis: Results From Part A of a Randomized, Placebo-Controlled, Three-Part, Phase 3 Study

Dubinsky_Eli Lilly_GHAPP 2021_AMAC urgency vs IBDQ_Poster.jpg

Absence of Bowel Urgency is Associated with Significantly Improved Inflammatory Bowel Disease Related Quality of Life in a Phase 2 Trial of Mirikizumabin Patients with Ulcerative Colitis


Disease burden and care-seeking behavior for IBS-C patients in the United States in the era of COVID-19


Rapid Onset of Time to First Spontaneous Bowel Movement (SBM) and Predictable Efficacy of Naloxegol: Pooled Analysis of Two Global Randomized Controlled Trials

Sands_Eli Lilly_GHAPP 2021_AMAG Prim EffSaf 12W-LB_Poster.jpg

Efficacy and Safety of Mirikizumab(LY3074828) After 12 Weeks Induction Treatment in a Phase 2 Study of Patients with Crohn’s Disease

Cave GHAPP 2021 QI Project Identifies 660 People with HCV 36x48.jpg

A Single-Center Continuous Quality Improvement Program Identifies 660 Hepatitis C Infected Persons in One Year

Dellon_EoE P3 PA EoE-IQ EoE-SQ PGIC_GHAPP 2021_poster_Sep 3.jpg

Dupilumab Reduces Symptom Burden and Improves Health-Related Quality of Life in Patients With Eosinophilic Esophagitis: Results From Part A of a Randomized, Placebo-Controlled, Three-Part, Phase 3 Study

GERD and Probiotics poster.jpg

Efficacy of Probiotic Use and Gastroesophageal Reflux Disease Symptom Management

Harrison_GHAPP21 1125 Primary Poster_KL04_FINAL_UPLOAD.jpg

Safety, Tolerability, and Biological Activity of AXA1125 and AXA1957 in a Prospective 16-Week Randomized, Placebo-Controlled Study in Subjects With NAFLD With and Without Type 2 Diabetes

Regueiro_Eli Lilly_GHAPP 2021_AMAG 12 and 52W Fatigue_Poster.jpg

Mirikizumab Therapy is Associated with Improved Fatigue in Patients with Moderately to Severely Active Crohn’s Disease


Pitfalls of Physician-Directed Treatment of Helicobacter pylori Infection: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data

CLDF-20-14 HCC Innovations Abstract Poster_GHAPP_48x36_v2.jpg

HCC Innovations

Dubinsky_Eli Lilly_GHAPP 2021_AMAC urgency (12 and 52W)_Poster.jpg

MirikizumabTreatment Improves Bowel Movement Urgency in Patients with Moderately to Severely Active Ulcerative Colitis

GHAPP-21-04  Abstract Poster_GHAPP_48x36_v2 (1).jpg

Clinical Update on the Management of Patients with Cirrhosis

Lim_HCC Oral Week 240 GHAPP 2021 v4.jpg

Impact of Treatment With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate on Hepatocellular Carcinoma Incidence in Patients with Chronic Hepatitis B

Sands_Eli Lilly_GHAPP 2021_AMAG EffSaf - (52W)_Poster.jpg

Efficacy and Safety of MirikizumabAfter 52-Weeks Maintenance Treatment in Patients with Moderate-to-Severe Crohn’s Disease

Thelen, Kendall.jpg

Implementing a Hepatitis C Compliance Program

Become a GHAPP Member

GHAPP Membership
bottom of page